LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models-Reference-Cited by-同舟云学术

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models

Published:2021-03-12 Issue:11 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Baba Rina¹^ORCID,Matsuda Satoru¹^ORCID,Arakawa Yuuichi¹,Yamada Ryuji¹,Suzuki Noriko¹,Ando Tatsuya²^ORCID,Oki Hideyuki³^ORCID,Igaki Shigeru³,Daini Masaki¹,Hattori Yasushi¹^ORCID,Matsumoto Shigemitsu¹,Ito Mitsuhiro¹,Nakatani Atsushi¹^ORCID,Kimura Haruhide¹^ORCID

Affiliation:

1. Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

2. Computational Biology, Research, Takeda Pharmaceutical Company Limited 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

3. Biomolecular Research Laboratories, Research, Takeda Pharmaceutical Company Limited 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

Abstract

LSD1 inhibitor TAK-418 could be a therapeutic option for neurodevelopmental disorders via normalization of gene expression.

Funder

Takeda Pharmaceutical Company Limited.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference38 articles.

1. Synaptic, transcriptional and chromatin genes disrupted in autism

2. Characteristics of fetal anticonvulsant syndrome associated autistic disorder

3. Maternal immune activation and abnormal brain development across CNS disorders